Momentum: MACD histogram -0.178 and negatively expanding → downside momentum is strengthening, not stabilizing.
RSI(6): 23.17 → oversold/washed-out short-term conditions, but oversold can persist in a downtrend.
Key levels: Pre-market ~16.88 is just above S1=16.834; a clean break below S1 opens room toward S2=16.263. Pivot resistance overhead at 17.758, then R1=18.683.
Pattern-based bias (similar candlesticks): +1.36% next day probability skew, but -5.98% next week and -2.38% next month → near-term bounce possible, but broader short-horizon drift is down.
Options Data
Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning: Put open interest 268 vs call open interest 20 → extremely put-heavy (OI P/C=13.4), consistent with defensive/bearish sentiment or heavy hedging.
Activity: Today’s options volume is 0 (no meaningful tape signal); ratios are driven by open interest rather than fresh flow.
Volatility: 30D IV ~134% vs historical vol ~43% with IV percentile ~95.6% → options are pricing very large moves; sentiment is cautious and downside protection appears crowded.
Technical Summary
Sell
9
Buy
4
Positive Catalysts
Strategic/tech catalyst: Collaboration with iotaMotion and FDA 510(k) clearance for pediatric use (age 4+) supports expansion into robotic-assisted procedures; capital-light model and diversified revenue streams highlighted in news.
Institutional flow: Hedge funds are buying; reported buying amount up ~114% QoQ.
Upcoming event: QDEC 2025 earnings on 2026-03-05 (after hours) could re-rate shares if the path to breakeven/free cash flow improves.
Street view: Recent initiations at Buy with $23–$24 price targets signal confidence in share gains and sustained low-double-digit revenue growth.
Neutral/Negative Catalysts
aligns with defensive positioning and/or bearish expectations.
Profitability trend improving but still loss-making: Net income -$11.77M (improved 48.67% YoY); EPS -0.50 (improved 47.06% YoY).
Gross margin: 73.92% (+0.69% YoY) → strong margin profile and modest improvement, supportive of operating leverage if growth persists.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent coverage trend: Two new initiations (Canaccord and TD Cowen) both at Buy, with $24 and $23 price targets.
Rating/target direction: Net positive (new bullish coverage rather than downgrades/cuts in the provided data).
Wall Street pros: Clear pediatric orthopedics leadership, visibility to market-share gains (trauma/deformity/scoliosis), expectation of sustained low-double-digit growth and improving EBITDA with near-term FCF breakeven potential.
Wall Street cons (implied): Recent guidance lowering mentioned as a de-risking event (suggests prior growth expectations were reset); current price action indicates the market remains skeptical despite the positive long-term narrative.
Wall Street analysts forecast KIDS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KIDS is 23 USD with a low forecast of 20 USD and a high forecast of 26 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast KIDS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KIDS is 23 USD with a low forecast of 20 USD and a high forecast of 26 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.590
Low
20
Averages
23
High
26
Current: 16.590
Low
20
Averages
23
High
26
TD Cowen
Buy
initiated
$23
AI Analysis
2026-01-26
Reason
TD Cowen
Price Target
$23
AI Analysis
2026-01-26
initiated
Buy
Reason
TD Cowen initiated coverage of OrthoPediatrics with a Buy rating and $23 price target. The firm says OrthoPediatrics is the "clear leader" in pediatric orthopedics, with visibility to "outsized" market share in trauma, deformity and scoliosis. The company's financial profile should support sustained low-double-digit revenue growth, improving EBITDA, and near-term free cash flow breakeven, none of which is priced into the stock's valuation, the analyst tells investors in a research note.
Canaccord
Caitlin Roberts
initiated
$24
2025-12-10
Reason
Canaccord
Caitlin Roberts
Price Target
$24
2025-12-10
initiated
Reason
Canaccord analyst Caitlin Roberts initiated coverage of OrthoPediatrics with a Buy rating and $24 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KIDS
